hackint0sh/New-Dataset huggingface dataset:
Cephalometric tracing from Giannì analysis will be performed at the baseline (T0) and after 18 months of treatment (T1). conditions: Skeletal Malocclusion studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 40 type: ESTIMATED name: AMCOP group name: High-pull headgear measure: Change in cephalometric angular measurements measure: Linear regressions measure: Change in cephalometric linear measurements sex: ALL minimumAge: 7 Years maximumAge: 11 Years stdAges: CHILD facility: Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia city: Pavia state: Lombardy zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06281600 id: REC: 23/SW/0042 id: 326109 type: OTHER domain: IRAS ID briefTitle: An Intervention Study Using HMOs to Improve IBS Symptoms acronym: GUT-HEAL-IBS overallStatus: RECRUITING date: 2024-02-20 date: 2025-08-20 date: 2025-09-20 date: 2024-02-28 date: 2024-02-29 name: Glenn Gibson class: OTHER name: Royal Berkshire NHS Foundation Trust briefSummary: There is now strong evidence implicating the human gut microbiota in many gastrointestinal diseases, including irritable bowel syndrome (IBS). Importantly, this enteric population is susceptible to dietary intervention and represents an exciting target for the prevention and treatment of gut mediated disorders. This study will investigate microbial components and activities associated with the gut microbiome, using a global systems biology approach to explore the capacity of a human milk carbohydrate intervention in modulating this microbial community to target IBS, with the primary objective of improving IBS symptoms.
IBS is a highly prevalent gastrointestinal (GI) disorder with significant negative impact on quality of life of patients and high healthcare costs. Although prognosis of IBS is benign, it is a disorder that poses a considerable burden on the individual sufferer and society. Patients typically present with chronic abdominal pain and an altered bowel habit, frequently accompanied by bloating and distension. Often, IBS will afflict sufferers for life, with flares of activity followed by periods of remission. Incidence commonly peaks in the third and fourth decades of life.
IBS is suggested to be a disorder of gut-brain interaction, and alterations of the microbiota-host interactions at the mucosal border may cause symptoms such as those previously mentioned. Therefore, microbiota-targeted interventions may benefit some people with IBS by beneficially modulating the gut microbiome. Several studies have confirmed that prebiotics, such as galactooligosaccharides (GOS), are able to successfully stimulate gut bifidobacteria and alleviate symptoms in IBS. Prebiotics are defined as "a substrate that is selectively utilised by host microorganisms conferring a health benefit" \[8\]. These studies suggest that prebiotics may have potential as therapeutic agents in IBS.
Breastmilk is known to play a crucial role in the development of infants, providing key nutrients and immunological compounds important for initial protection against pathogens \[9\]. Among these compounds, human milk oligosaccharides (HMOs) represent the third most important component of breastmilk after lipids and lactose. HMOs have also been investigated for potential health benefits in adults, including their potential role as prebiotics for improved gut microbiota modulation.
Studies looking specifically at HMO interventions in humans with IBS are sparse. These include a phase II, parallel, RCT in 58 IBS volunteers by Iribarren et al. and an open-label trial with 245 IBS participants from 17 sites across USA by Palsson et al.. None have been sufficiently powered to a degree which could influence clinical practice, but crucially tolerability and safety profiles of HMOs investigated, to date, have been consistently high.
This study will look specifically at patients with all IBS subtypes, an area where there is a real therapeutic gap and clinical need for safe, effective therapy to improve quality of life. Participants will be randomly allocated to be given either the HMO or a placebo, with neither the patient nor the researchers knowing which they are receiving (randomised and double blind design). They will take this HMO or placebo for 28 days (randomly distributed), and then stop taking it in a 'washout' period of 28 days, allowing the gut microbiota to return to baseline. Then, the participants will take the other intervention (placebo or prebiotic, whichever they did not take in the first half of the study) for 28 days, then have a further washout period of 14 days. The study will then be over.
With this proposal, the aim is to explore how HMOs affect the gut microbiota and whether they can do so in a manner that positively influences patients with IBS. The investigators also hope to develop molecular profiling as part of a research toolkit for gut microbiome-based HMO supplement studies. conditions: Irritable Bowel Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is a 16-week, randomised, placebo-controlled, double-blinded crossover trial. We aim to recruit 44 participants with IBS. These participants will be screened and classified into a particular IBS subtype. After a 14-day baseline period, participants will be randomised to orally consume either 5g of HMO for 28 days, or a placebo for 28 days. This will be administered at the University of Reading. All participants will then stop taking the product for 28 days (wash out period) and then swap treatment type and have 28 days of either placebo or HMO. This is then followed by another 14 days without any product. During the study, participants will be asked to complete a 24-hour food recall weeks 0 and 16. Additionally, participants will complete validated questionnaires (IBS-Symptom Severity Score, anxiety and depression score and Pittsburgh Sleep Quality Index (PSQI) every time they provide urine and faecal samples at each visit. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Every individual involved in undertaking this trial will be blinded. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: Human milk oligosaccharide name: Maltodextrin placebo measure: IBS-SSS measure: Change in anxiety and depression scores (ADS) measure: Improvement of the Pittsburgh Sleep Quality Index (PSQI). measure: Changes in faecal microbiota e.g. Bifidobacterium sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The University of Reading status: RECRUITING city: Reading state: Berkshire zip: RG6 6LA country: United Kingdom name: Patricia Sanz Morales role: CONTACT phone: +447843865554 email: p.sanzmorales@pgr.reading.ac.uk name: Glenn Gibson, Prof. role: SUB_INVESTIGATOR lat: 51.45625 lon: -0.97113 hasResults: False
nctId: NCT06281587 id: SNFyodorov briefTitle: Pathogenetic Risk Factors for Corneal Graft Rejection overallStatus: COMPLETED date: 2011-01 date: 2019-01 date: 2019-01 date: 2024-02-28 date: 2024-02-28 name: The S.N. Fyodorov Eye Microsurgery State Institution class: OTHER_GOV briefSummary: There are many predictors that may influence the development of corneal graft rejection after penetrating keratoplasty. In our study investigators analysed the results of keratoplasty and the risk factors for graft rejection.
Investigators analysed data from 493 patients who underwent penetrating keratoplasty between 2011 and 2019. Keratoplasty outcomes were followed up at subsequent clinic visits until December 2021. Then, 93 medical records were selected (taking into account the completeness of the medical records) and divided into two groups based on the primary diagnosis that was an indication for keratoplasty: high-risk and low-risk patients. Investigators then estimated the survival time (clear graft) of the corneal graft using Kaplan-Meier statistical survival analysis. Investigators also investigated the factors that influence corneal graft opacity. conditions: Graft Rejection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 93 type: ACTUAL name: penetrating keratoplasty measure: Cohort group Kaplan-Meier survival analysis (clear graft engraftment) sex: ALL minimumAge: 13 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT city: Krasnodar zip: 350012 country: Russian Federation lat: 45.04484 lon: 38.97603 hasResults: False
nctId: NCT06281574 id: S67346 briefTitle: What Are the Determinants for RTW After SA acronym: RTW after SA overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-13 date: 2025-02-01 date: 2025-02-01 date: 2024-02-28 date: 2024-03-06 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Shoulder arthroplasty is becoming increasingly common, due to ageing of the population. Historically, surgeons have been reluctant to use a shoulder replacement in younger patients. During the last decades however, there was an improvement of surgical techniques and implants which resulted in the fact that these procedures are nowadays more frequently used in younger patients. Combined with the increasing life expectancy and the increased age of retirement, both elderly and younger patients hope to continue their jobs after prosthetic replacement.
This study aims to analyze the RTW percentage in a Belgian cohort of patients with a shoulder replacement. This study hopes to identify factors that might influence the RTW. conditions: Shoulder Arthroplasty studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Questionnaires measure: Return to work measure: Type of shoulder arthroplasty measure: WORQ-UP (work-related questionnaire for upper extremity disorders) measure: SSV (Subjective Shoulder Value) measure: SST (Dutch translation of the Simple Shoulder Test) measure: OSS (Oxford Shoulder Score) measure: Self-made questionnaire measure: Belgisch Kenniscentrum over welzijn op het werk (BeSWIC) sex: ALL minimumAge: 18 Years maximumAge: 63 Years stdAges: ADULT facility: UZ Leuven city: Leuven state: Vlaams-Brabant zip: 3000 country: Belgium lat: 50.87959 lon: 4.70093 hasResults: False
nctId: NCT06281561 id: FirstAHXiamenU-YB briefTitle: Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-30 date: 2024-12-31 date: 2024-02-28 date: 2024-04-16 name: The First Affiliated Hospital of Xiamen University class: OTHER briefSummary: The goal of this clinical trial is to learn about the effect of preoperative nasal spry with dexmedetomidine on postoperative sleep disturbance in young to middle-aged women undergoing hysteroscopy. The main questions it aims to answer are:1) what is the incidence of postoperative sleep disturbance in unisex patients who receive propofol anesthesia. 2) The preventive effect of preanesthesia nasal spray dexmedetomidine on postoperative sleep disturbance.
Researchers will compare the effects of 0.2 or 0.5 ug/kg dexmedetomidine to see if it help improve postanesthesia sleep quality. conditions: Postoperative Sleep Disturbance studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Normal Saline name: Dexmedetomidine measure: Change from baseline sleep quality at after intervention measure: Pittsburgh sleep quality index(PSQI) measure: Early recovery evaluated by Aldrete rating scale measure: Later Recovery evaluated by QoR-40 questionnaire sex: FEMALE minimumAge: 23 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06281548 id: 23-2937 id: 1F31DA058452 type: NIH link: https://reporter.nih.gov/quickSearch/1F31DA058452 briefTitle: Feasibility and Acceptability of a Stigma Text Message Intervention for People Who Use Drugs overallStatus: RECRUITING date: 2024-02-29 date: 2024-04-30 date: 2024-04-30 date: 2024-02-28 date: 2024-03-06 name: University of North Carolina, Chapel Hill class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages are designed to address four components of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use.
This study is a single-group pilot trial to determine whether the intervention is feasible and acceptable to participants. All participants will receive the intervention. The primary outcomes are changes in stigma resistance and self-stigma from baseline to 4-week follow-up using self-report. Implementation and process outcomes will be measured to inform future intervention refinement. conditions: Stigma, Social conditions: Substance Use studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: RESTART measure: Change in Stigma Resistance Scale (SRS) Score measure: Change in Substance Abuse Self-Stigma Scale (SASSS) Score measure: Percentage of Prospective Participants Eligible for Participation (Feasibility - Recruitment) measure: Percentage of Prospective Participants Recruited into Study (Feasibility - Enrollment) measure: Time to Sample Saturation (Feasibility - Recruitment) measure: Percentage of Participants Retained in Study (Feasibility - Retention) measure: Theoretical Framework of Acceptability (TFA) User Questionnaire Score (Acceptability - User) measure: Percentage of Participants with High Text Message Frequency (Feasibility - User) measure: Percentage of Participants with High Text Messaging Comfort (Feasibility - User) measure: Percentage of Participants with Cell Phone Device Challenges (Feasibility - User) measure: Percentage of Participants with Cell Phone Plan Challenges (Feasibility - User) measure: Percentage of Participants who Read Messages Daily (Feasibility - User) measure: Change in Adult Dispositional Hope Scale Score measure: Change in Rosenberg Self-Esteem Scale Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SHRPS Syringe Service Program status: RECRUITING city: Portsmouth state: Ohio zip: 45662 country: United States name: Adams L Sibley, MPH role: CONTACT phone: 423-227-9198 email: asibley@live.unc.edu name: Abby Spears role: CONTACT phone: 740-357-9773 email: abby@sciotoconnect.org lat: 38.73174 lon: -82.99767 hasResults: False
nctId: NCT06281535 id: 21789 briefTitle: Early Versus Conventional Loading for Fully Guided Immediate Implant Placement overallStatus: NOT_YET_RECRUITING date: 2024-02-20 date: 2024-05-31 date: 2024-06-15 date: 2024-02-28 date: 2024-02-28 name: Ain Shams University class: OTHER name: Assiut University briefSummary: Conventional loading protocol following implant placement 3 -6 months is considered the gold standard. However, early loading following 2 months after implant placement decreases the time and had a good survival rate. conditions: Dental Implant studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Implant loading measure: Implant stability sex: ALL minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06281522 id: University of Health Sciences briefTitle: The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus) acronym: Echinococcusis overallStatus: RECRUITING date: 2023-12-18 date: 2024-03-30 date: 2024-06-30 date: 2024-02-28 date: 2024-02-28 name: Abdullah Adiyaman class: OTHER briefSummary: This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice. conditions: Lung Hydatid Cyst studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 54 type: ESTIMATED name: Operated patients with hydatid cyst of the lung measure: Calculation of laboratory markers sex: ALL minimumAge: 18 Years maximumAge: 83 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences, Van Training and Research Hospital status: RECRUITING city: Van country: Turkey lat: 38.49457 lon: 43.38323 hasResults: False
nctId: NCT06281509 id: S68374 briefTitle: Palmaris Longus Muscle and Dupuytren acronym: Palmaris overallStatus: RECRUITING date: 2024-02-16 date: 2025-02-01 date: 2025-02-01 date: 2024-02-28 date: 2024-03-07 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Dupuytren disease is a medical condition characterized by the painless formation of nodules in the palm of the hand. Cords are formed on the palmar fascia, a connective tissue sheet in the palm of the hand. This fascia is seen as the vestigial remnant of the palmaris longus tendon. The PLM attaches to the fascia palmaris. A muscle that not everyone has and can therefore be clearly missed. This raises the question of whether the presence of the musculus palmaris longus has any association with the development, recurrence and/or progression of DD and contractures. To investigate a potential predisposition, this study intend to assess the prevalence of the PLM in a group of individuals affected by DD and compare it with a control group (age matched, no signs of DD) without the condition. conditions: Dupuytren's Disease studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups: Patients with Dupuytren Disease and healthy control group. They will be age matched (50 years of age or higher) with the objective to have a proportionate division (50/50) between the genders. primaryPurpose: DIAGNOSTIC masking: NONE maskingDescription: No masking will be done in this study count: 240 type: ESTIMATED name: Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands. name: Ultrasound measure: PLM in the DD versus control measure: PML in mild versus severe DD-group measure: PLM presence in DD affected group measure: PLM presence in control group measure: Dominant versus non-dominant hand measure: Male versus female population sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitaire Ziekenhuizen KU Leuven status: RECRUITING city: Leuven state: Vlaams-Brabant zip: 3000 country: Belgium name: Ilse Degreef, Prof. Dr. role: CONTACT phone: +32 16 33 88 43 email: ilse.degreef@uzleuven.be name: Anna Tarasiuk role: CONTACT phone: +32 16 33 88 18 email: orthopedie.research@uzleuven.be lat: 50.87959 lon: 4.70093 hasResults: False
nctId: NCT06281496 id: Rigshospitalet, Hematology briefTitle: AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation acronym: AlloCare overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-10-01 date: 2026-12-01 date: 2024-02-28 date: 2024-02-29 name: Rigshospitalet, Denmark class: OTHER name: Danish Cancer Society briefSummary: A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase. conditions: Hematological Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: One site, two arm randomized controlled trial primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 100 type: ESTIMATED name: AlloCare measure: EORTC Quality of Life Survivorship Core questionnaire (EORTC-QOL-SURV100) measure: Modified 7-day Lee Chronic-versus-Host Disease Symptom Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rigshospitalet city: Copenhagen zip: 2100 country: Denmark name: Mette Schaufuss Engedal, MSc role: CONTACT phone: +45 51896699 email: mette.schaufuss.engedal@regionh.dk name: Mary Jarden, Professor role: CONTACT email: mary.jarden@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06281483 id: APCs in chronic skin ulcers briefTitle: PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers overallStatus: RECRUITING date: 2024-01-01 date: 2025-01-01 date: 2026-01 date: 2024-02-28 date: 2024-02-28 name: Kafrelsheikh University class: OTHER name: Helwan University briefSummary: To compare the therapeutic efficacy of PRP and PRF: two relatively newer modalities in the management of chronic non-healing ulcers versus conventional treatment. conditions: Chronic Non-healing Skin Ulcers studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: platelet-rich plasma name: platelet-rich fibrin name: Surgical debridement, normal saline washing and dressing coverage measure: Objective assessment of ulcer size for effectiveness, using Image J software. measure: Pain assessment measure: Any adverse effects related to treatment modality sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Badr Hospital - Helwan University and Kafrelseikh University Hospital status: RECRUITING city: Cairo country: Egypt name: Mohamed Aboshabana Hussein, Assistant Lecturer role: CONTACT phone: 01007981008 email: dr.mohamedaboshabana@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False